Ciprofloxacin, 500 mg 10 pcs

A broad-spectrum antimicrobial agent of the group of fluoroquinolones. It has a bactericidal effect. Inhibits DNA-GiRase and inhibits the synthesis of bacterial DNA.

Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

Active against Staphylococcus spp. (including penicillinase producing and non-producing strains, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Ciprofloxacin is active against bacteria producing β-lactamases.

Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides are resistant to ciprofloxacin. Its action against Treponema pallidum has not been studied sufficiently.

Indications

Infectious and inflammatory diseases caused by ciprofloxacin-sensitive microorganisms, including respiratory tract diseases, abdominal, pelvic, bone and joint infections and skin infections.including diseases of the respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of ENT organs. Treatment of postoperative infections. Prophylaxis and treatment of infections in patients with lowered immunity.

For topical application: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious ocular lesions after trauma or ingestion of foreign bodies. Preoperative prophylaxis in ophthalmosurgery.

Active ingredient

Composition

On one tablet:

The active ingredient:

Ciprofloxacin hydrochloride – 582.20 mg (ciprofloxacin – 500.00 mg);

Associates of the tablet core:

Corn starch, 7.20 mg;

Partially pregelatinized corn starch (Starch 1500), 60.00 mg;

Microcrystalline cellulose – 86.20 mg;

crospovidone (collidone CL) – 15.40 mg;

/p>

magnesium stearate – 7.60 mg;

lactose monohydrate – 26.60 m;

talc – 14.80 mg.

Ancillary film ingredients:

Hypromellose – 11.56 mg;

polyethylene glycol 6000 – 4.88 mg;

titanium dioxide. – 1.78 mg;

Polysorbate 80 – 1.78 mg.

Interaction

In concomitant use of ciprofloxacin with didanosine absorption of ciprofloxacin is reduced due to the formation of ciprofloxacin complexons with aluminum and magnesium buffers contained in didanosine.

Concomitant use with warfarin increases the risk of bleeding.

Concomitant use of ciprofloxacin and theophylline may increase plasma concentrations of theophylline, increase T1/2theophylline, which leads to an increased risk of theophylline-related toxic effects.

Concomitant administration of antacids as well as drugs containing aluminum, zinc, iron, or magnesium ions may cause decreased absorption of ciprofloxacin, so an interval between administration of these drugs should be at least 4 hours.

Directions for use

Individual. Orally – 250-750 mg 2 times a day. The duration of treatment is from 7-10 days to 4 weeks.

For intravenous administration, a single dose is 200-400 mg, the frequency of administration is 2 times/day; treatment duration is 1-2 weeks, or more if necessary. It is possible to administer by IV fluids, but drip infusion for 30 minutes is preferable.

When applied topically, 1-2 drops are placed into the lower conjunctival sac of the affected eye every 1-4 hours. The intervals between instillations may be increased after the condition improves.

The maximum daily dose for adults when taken orally is 1.5 g.

Special Instructions

In patients with impaired renal function, dosage regimen should be adjusted. Caution is used with caution in elderly patients, in atherosclerosis of cerebral vessels, cerebral circulation disorders, epilepsy, convulsive syndrome of unclear etiology.

Patients should get plenty of fluids during treatment.

In case of persistent diarrhea ciprofloxacin should be discontinued.

In concomitant intravenous administration of ciprofloxacin and barbiturates, HR, BP, ECG should be monitored. During treatment it is necessary to control blood concentrations of urea, creatinine, hepatic transaminases.

In the course of treatment a decrease in reactivity is possible (especially in concomitant use with alcohol).

Ciprofloxacin should not be administered subconjunctivally or directly into the anterior chamber of the eye.

Contraindications

Side effects

Digestive system disorders: nausea, vomiting, diarrhea, abdominal pain, increased activity of liver transaminases, ALP, LDH, bilirubin, pseudomembranous colitis.

CNS disorders: headache, dizziness, fatigue, sleep disorders, nightmares, hallucinations, fainting, visual disorders.

Urinary system disorders: crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase in serum creatinine.

Hematopoietic system disorders: eosinophilia, leukopenia, neutropenia, platelet count changes.

Cardiovascular system disorders: tachycardia, heart rhythm disorders, arterial hypotension.

Allergic reactions: skin itching, urticaria, Quincke’s edema, Stevens-Johnson syndrome, arthralgia.

Systemic reactions associated with chemotherapeutic action: candidiasis.

Local reactions: soreness, phlebitis (when injected intravenously). When using eye drops in some cases mild soreness and conjunctival hyperemia are possible.

Others: vasculitis.

Similarities